Glucosamine has been one of the most widely used over-the-counter supplements for decades, taken by millions of older adults to ease joint pain and slow the progression of osteoarthritis. A new study published on June 15, 2026, in Nature Metabolism, however, is prompting a sharp reconsideration of the supplement’s safety in one specific group: people who already have Alzheimer’s disease or related dementias.
The findings, drawn from a combination of human clinical records, post-mortem brain tissue, and experiments in mice, suggest that glucosamine may accelerate disease progression and raise mortality risk in patients with established dementia. For the supplement industry — and for caregivers of the more than 7 million Americans living with Alzheimer’s, according to the Alzheimer’s Association — the implications are significant.
What the New Research Found
Researchers at the University of Florida analyzed health records from more than 50,000 patients with Alzheimer’s-disease-related dementias (ADRD) and mild cognitive impairment (MCI). The full clinical analysis covered 24,481 ADRD patients and 41,884 individuals with MCI, with an average follow-up of about five years. Roughly 8% of each group reported using glucosamine supplements.
The key clinical finding: among patients with established ADRD, glucosamine use was associated with a 25% higher risk of death over the follow-up period compared with non-users. Notably, this signal did not appear in patients with mild cognitive impairment — a less advanced stage of cognitive decline.
To explore why, the team examined post-mortem human brain tissue and ran experiments in 5xFAD mice, a genetically modified strain used to model aggressive Alzheimer’s disease. They reported that glucosamine appears to drive hyperglycosylation — an excessive attachment of sugar molecules to proteins — that impairs nerve cell function. When the researchers blocked the relevant glycan formation in mice, memory performance improved.
Why Glucosamine? Why Now?
Glucosamine is an amino sugar naturally found in cartilage. Sold as glucosamine sulfate or glucosamine hydrochloride, it is one of the top-selling joint supplements in the United States, frequently combined with chondroitin. The National Center for Complementary and Integrative Health notes that evidence for glucosamine’s benefit in osteoarthritis is mixed, with some trials showing modest pain relief and others showing no effect beyond placebo.
Earlier observational research had even hinted at possible cardiovascular and longevity benefits in healthy adults, though those findings remain debated. The new Nature Metabolism work changes the conversation by drilling into a specific population — people already living with dementia — and pairing the clinical data with mechanistic experiments.
How the Mechanism May Work
Glucosamine feeds into the hexosamine biosynthetic pathway, which produces a molecule called UDP-GlcNAc. This molecule is used by the cell to add sugar tags to proteins, a process called O-GlcNAcylation. In moderation, that process is essential for healthy cell signaling. In excess, the researchers argue, it disrupts protein function in vulnerable neurons.
In the Alzheimer’s brain — already burdened by amyloid plaques, tau tangles, and impaired energy metabolism — additional glycosylation stress may push struggling neurons further toward dysfunction. The mouse work supported this idea: blocking the relevant enzymes preserved memory in the Alzheimer’s model.
Important Caveats
Several limitations deserve attention before any patient or caregiver changes their routine:
- The clinical data are observational. Even with statistical adjustment, people who choose glucosamine may differ from non-users in ways that affect mortality risk.
- The 5xFAD mouse model represents aggressive, early-onset Alzheimer’s. It does not perfectly mirror the more common late-onset disease.
- No signal was seen in MCI patients, suggesting the risk, if real, may be specific to more advanced disease.
- Causation has not been established. The authors and outside experts have emphasized that more research is needed before clinical recommendations change.
As Courtney Kloske, PhD, of the Alzheimer’s Association told Medical News Today, the results “should not be interpreted as a recommendation to start or stop glucosamine without consulting a healthcare provider.” Harris Gelbard, MD, PhD, separately noted that the study “carries enough weight to further define relationships between age of onset of glucosamine supplementation and specific dementia types.”
What This Means for Healthy Adults
For people without cognitive impairment, the new study is not a direct warning. It does not address whether glucosamine raises dementia risk in healthy users, nor does it overturn previous mixed evidence on joint pain relief. The participants in the clinical analysis already had dementia diagnoses; the mechanistic experiments used a disease model.
That said, the findings underscore a broader point that public health researchers have made for years: supplements are not automatically safe simply because they are sold over the counter. The U.S. Food and Drug Administration regulates supplements far more loosely than prescription drugs, and population-level safety signals often emerge years after a product becomes a daily staple for millions.
Joint Pain Without Glucosamine: What the Evidence Supports
For osteoarthritis, especially of the knee and hip, several non-supplement strategies are backed by stronger evidence than glucosamine:
- Structured exercise. Land- and water-based exercise programs are first-line recommendations from the American College of Rheumatology and the Osteoarthritis Research Society International.
- Weight management. A reduction of body weight can meaningfully reduce knee load and pain.
- Physical therapy and strength training targeting the quadriceps and hip muscles.
- Topical NSAIDs such as diclofenac gel, which offer pain relief with lower systemic risk than oral medications.
- Anti-inflammatory dietary patterns such as the Mediterranean diet, which research suggests may help reduce joint inflammation.
The Bigger Question About Supplements and Cognition
The glucosamine findings join a small but growing list of supplements that have shown unexpected effects on brain health in older adults. High-dose vitamin A toxicity, certain herbal stimulants, and some sleep aids have all raised concerns. Cognitive vulnerability appears to amplify the harm — or the help — of bioactive compounds that healthier brains tolerate without issue.
The practical lesson: supplement choices matter more, not less, as people age. A medication review with a clinician or pharmacist — including over-the-counter products — is especially worthwhile for anyone with a memory diagnosis or strong family history of dementia.
Bottom Line
One study does not prove that glucosamine harms people with dementia. But the convergence of clinical, post-mortem, and animal evidence is strong enough that families and clinicians caring for people with Alzheimer’s disease may want to revisit the question with fresh eyes. Anyone currently taking glucosamine should not stop abruptly without a conversation with their healthcare provider — and anyone considering it for joint pain has well-supported alternatives worth exploring first.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.